Monopar Therapeutics

US · MNPR #3671 by market cap Listed 2019

82.54 -1.24 -1.48%

Live - 5344 symbols - heartbeat 396s ago · 2026-10-08 10:00

Pre-market 84.54 +0.91%

After-hours 83.80 +0.02%

Overnight 83.03 -0.90%

Market cap: 554.02M
P/E (TTM): -37.52
P/B: 4.23
EPS: -1.85
Div yield: 0.00%
52W pos: 43%

Reader sentiment Are you bullish or bearish on MNPR?

Anonymous reader poll. Unscientific, not investment advice.

About Monopar Therapeutics

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Founded: 2014
CEO: Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D.
Employees: 22
Headquarters: Wilmette, Illinois, United States of America
Fiscal year end: 12-31
Website: monopartx.com

Company profile

Exchange: US
Symbol: MNPR
Market-cap rank: #3671
Listing date: 2019-12-19
Market cap: 554.02M
Float cap: 368.73M
Shares out: 6.71M
Float shares: 4.47M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 10:00:07 · For reference only, not investment advice and not tailored to your situation.